The genetic architecture of postoperative delirium after major surgery and its

relationship with non-postoperative neurocognitive conditions

Richard A. Armstrong,[1*] Paul Yousefi,[1,2] Ben Gibbison,[3] Golam M Khandaker,[1,2,4,5]

Tom R Gaunt[1,2]

1 MRC Integrative Epidemiology Unit, Bristol Medical School, University of

Bristol, Bristol, UK.

2 NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and

Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

3 Bristol Medical School, University of Bristol, Bristol, UK.

4 Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK.

5 Centre for Academic Mental Health, Population Health Sciences, Bristol

Medical School, University of Bristol, Bristol, UK.

*Correspondence to: Richard A Armstrong

Email: ra17848@bristol.ac.uk

X: @drrichstrong

Short title: Genetic architecture of postoperative delirium

Abstract

Background

Postoperative delirium is the most common postoperative complication in older

individuals. Genome-wide association studies (GWAS) can provide insights into how

genetic factors influence postoperative risk. We examined the genetic architecture of

postoperative delirium after major surgery and its relationship with related cognitive

conditions (delirium of any type and Alzheimer's disease, including the *APOE* ε4

allele).

Methods and Findings

A GWAS was performed in UK Biobank to identify genetic variants associated with

postoperative delirium. These results were then used in genetic correlation and

polygenic risk score analyses to investigate shared genetic risk between

postoperative delirium and a) delirium of all causes, and b) Alzheimer's disease.

The GWAS (1016 cases, 139,148 controls) identified six Single Nucleotide

Polymorphisms (SNPs) that mapped to four genes (*APOE, TOMM40, APOC1* and

PVRL2); $p < 5 \times 10^{-8}$. Five SNPs remained significant after excluding pre-existing

dementia, and two after excluding subsequent dementia. The lead SNP was

rs429358, a missense variant of *APOE*. Genetic correlation and polygenic risk score

analyses revealed evidence of shared genetic architecture and risk between

postoperative delirium and Alzheimer's disease (rho = 0.68, p<0.001). The *APOE* ε4

isoform had a dose-response effect on risk (OR [95% CI] for one and two copies

1.75 [1.53 – 2.0] and 4.19 [3.25 – 5.41] respectively, p <0.001).

Conclusions

We identified genetic variants associated with increased risk of postoperative

delirium. We also found evidence of shared genetic liability with Alzheimer's disease

suggesting that individuals with genetic risk of Alzheimer's disease, even without

symptoms, may be at higher risk of postoperative delirium.

Introduction

Postoperative delirium is the most common postoperative complication in older

individuals, with an incidence of up to 65% (1,2). It has substantial health and

resource implications including increased morbidity, mortality and healthcare costs

(1,3). Hypotheses of the underlying mechanisms span a range of pathways including

release of excitotoxic neurotransmitters, neuronal injury and inflammation,

physiological stressors, metabolic derangements, electrolyte disorders and genetic

factors (1,2,4–8). Postoperative delirium has been associated with an increased risk

of cognitive decline and incident dementia (9) but there is conflicting evidence on

how the acute occurrence of postoperative delirium interacts with longer-term

cognitive decline and neurodegeneration (10).

Whilst the aging global population and increasing numbers of older adults

undergoing surgery have made perioperative brain health an increasing focus of

research and clinical initiatives (11), the ability of clinical teams to produce

personalised assessments of clinical risk for individuals remains limited. Improved

detection of underlying biological risk in conjunction with established clinical risk

factors could aid in preoperative risk prediction, facilitate better-informed shared-

decision making and allow targeting of multicomponent interventions to prevent

delirium (11) with potential reductions in morbidity, mortality and resource utilisation.

Population-based genome-wide association studies (GWAS) are a powerful

approach for identifying genetic risk factors associated with complex conditions of

multifactorial aetiology. Their results can aid prediction but also identify underlying

biological mechanisms and potential targets for intervention. They have been

extensively applied to a wide range of clinical phenotypes (12), but rarely to

postoperative delirium specifically. Previous GWAS that have included postoperative

neurocognitive complications have failed to identify any genome-wide significant

associations (13–15) - most likely because they suffered from limited sample sizes

and heterogeneity of outcomes.

This study aimed to evaluate the association between genetic variants genome-wide

and postoperative delirium following major surgery, and to explore whether

postoperative delirium shares genetic risk factors with related conditions, specifically

delirium of all causes and Alzheimer's disease. The limitations of previous studies

are addressed by defining a major surgery cohort in a large scale national biobank

and focusing on a single outcome phenotype.

Methods

Study Populations

The data source for the primary analysis was UK Biobank, a long-term prospective

cohort study that provides a large-scale biomedical database and research resource

containing genetic, lifestyle and health information from half a million UK participants

recruited between 2006 and 2010 (http://www.ukbiobank.ac.uk). The UK Biobank

study was approved by the North-West Multi-centre Research Ethics Committee and

all participants provided written informed consent (16). Additionally, publicly available

GWAS summary statistics from the FinnGen study were used as an external cohort

for genetic correlation analyses. FinnGen is a large-scale genomics initiative that has

analysed over 500,000 Finnish biobank samples and correlated genetic variation

with health data to understand disease mechanisms and predispositions. The project

is a collaboration between research organisations and biobanks within Finland and

international industry partners (17).

Genotyping

UK Biobank genotyping was performed by Affymetrix using two purpose-designed

arrays. Genotype data were quality controlled, phased and ~96 million genotypes

were imputed using the Haplotype Reference Consortium and UK10K haplotype

resources. FinnGen genotyping used a ThermoFisher Axiom custom chip array with

imputation to a reference dataset derived from Finnish whole-genome sequences.

Further information on the methods and QC pipelines are available (16,18).

Inclusion and exclusion criteria

113 Eligible participants were those undergoing major, inpatient surgery after their date of

114 enrolment in UK Biobank. Linked hospital inpatient data is available for all UK

115 Biobank participants with follow-up to 31 May 2022 for Wales, 31 August 2022 for

116 Scotland and 31 October 2022 for England (19). Major surgery was defined by

117 OPCS4 code using the Bupa Schedule of Procedures and Abbott classification

118 (20,21) and diagnoses of delirium were identified using International Classification of

119 Diseases, Tenth Revision (ICD-10) code F05. Exclusion criteria included planned

120 day case surgery and a previous diagnosis of delirium (see Supplementary Methods

121 for more detail on phenotype definition and exclusions).

123 *Outcome definition*

124 The primary outcome was a first diagnosis of delirium within 30 days of surgery.

125 Controls were defined as those undergoing major surgery with no delirium diagnosis

126 within 30 days.

128 *Genome-wide Association Study (GWAS)*

129 Case–control GWAS adjusted for sex, genetic chip and the first ten principal

130 components was performed using regenie (v3.2.2) (22). Quality control and ancestry

131 definition were performed by previously established MRC-IEU workflows and

132 methods (23). Post-hoc analyses were conducted using Functional Mapping and

133 Annotation of Genome-Wide Association Studies (FUMA GWAS (24)). Independent

134 significant SNPs were defined as those meeting a genome-wide significance

135 threshold of $p < 5 \times 10^{-8}$ and independent of each other at $r^2 < 0.6$. Lead SNPs were

identified from independent significant SNPs at $r^2 < 0.1$. Gene-based analysis was

performed using Multi-marker Analysis of GenoMic Annotation (MAGMA (25)).

The primary GWAS analysis did not include additional clinical covariates as they may

be mediators of genetic risk or colliders given the selection of a surgical patient

cohort. To explore the robustness of the primary analysis the following sensitivity

analyses were performed: a) with adjustment for age; b) after excluding participants

who had a previous dementia diagnosis; c) excluding participants who had a

previous dementia diagnosis or were diagnosed with dementia after the index

procedure; and d) stratified by cardiothoracic/non-cardiothoracic surgery.

Post-GWAS follow-up analyses

Exploratory follow-up analyses were informed by the results of the primary GWAS

analysis. Two approaches were taken to formally assess shared genetic architecture

between postoperative delirium and a) delirium of any type; b) Alzheimer's Disease:

genetic correlation analysis and polygenic risk scoring.

Genetic correlation analysis

Genetic correlation analyses were performed between the UKB GWAS results

presented here and the external FinnGen study cohort. GWAS summary statistics

(Freeze 9, https://r9.finngen.fi/) were obtained for a) delirium (any cause); and b)

Alzheimer's disease. Local Analysis of [co]Variant Association (LAVA (26)) was used

to analyse bivariate local genetic correlation between these phenotypes and

postoperative delirium (using the summary statistics from the primary GWAS

analysis in UK Biobank).

Polygenic risk score analysis

Polygenic risk scores calculate a weighted sum of risk based on alleles associated

with a disease or outcome phenotype. The Polygenic Score Catalog

(https://www.pgscatalog.org/) was used to identify polygenic risk scores for

Alzheimer's disease. No polygenic risk scores were identified for delirium. The

pgsc_calc workflow (27) was used to download, variant match and calculate

individual polygenic scores for the primary UK Biobank cohort. Individual scores

were then centred and scaled before being summed and averaged. Odds ratios for

the association between increasing quintile of polygenic risk score for Alzheimer's

disease and postoperative delirium were estimated by logistic regression with

adjustment for age and sex using the *glm* function in R (version 4.4.0).

Apolipoprotein E (APOE) genotype analysis

It has been recommended that the *APOE* region of chromosome 19 should be

excluded from Alzheimer's disease polygenic risk scores, with the *APOE* ε4 allele

included as an additional covariate in modelling, due to its outsize effect relative to

other regions across the genome (28). The subset of polygenic scores identified

above which did not include the *APOE* region (defined as a 10 kilobase window

either side of region from the start position of *TOMM40*, 45,394,477, to the stop

position of *APOC1*, 45,422,606, build 37/hg19 (28)) were therefore considered in an

additional analysis, adjusted for age, sex and *APOE* ε4 allele count (0, 1, 2).

Results

Participant characteristics

A total of 1016 cases of postoperative delirium and 139,148 controls were identified

(Figure 1). Individuals who developed postoperative delirium tended to be older,

male and had higher prevalence of comorbidities (Table 1). Compared to controls, a

higher proportion of patients in the postoperative delirium group underwent

emergency (532 (52%) vs 29,530 patients (21%)) and cardiothoracic surgery (172

(17%) vs 5041 patients (3.6%)).

Table 1 Participant characteristics for postoperative delirium cases and controls.

	Cases n = 1016	Controls n = 139,148	p-value
Age (yr), mean (SD)	72 (6)	64 (8)	<0.001
Sex, number (%)			<0.001
Female	384 (38)	77,244 (56)	
Male	632 (62)	61,904 (44)	
Ethnicity, number (%)			0.2
Asian or Asian British	9 (0.9)	2301 (1.7)	
Black or Black British	10 (1.0)	1644 (1.2)	
Chinese	0 (0)	239 (0.2)	
Mixed	5 (0.5)	675 (0.5)	
Other ethnic group	3 (0.3)	984 (0.7)	
White	978 (97)	132,676 (96)	
Missing	11 (1.1)	629 (0.5)	
Charlson Comorbidity Index, median (IQR)	1 (0–3)	0 (0–1)	<0.001
Missing	25 (2.5)	15,817 (11)	
Admission method, number (%)			<0.001
Elective	434 (43)	106,725 (77)	
Emergency	532 (52)	29,530 (21)	
Maternity	0 (0)	113 (<0.1)	
Not known	0 (0)	29 (<0.1)	

Transfer	50 (4.9)	2751 (2.0)
Surgical specialty, number (%)		<0.001
Cardiothoracic surgery	172 (17)	5041 (3.6)
General surgery	196 (19)	26,436 (19)
Neurosurgery	55 (5.4)	5192 (3.7)
Other	186 (18)	36,532 (26)
Trauma and orthopaedics	338 (33)	53,722 (39)
Urology	37 (3.6)	10,628 (7.6)
Vascular	32 (3.1)	1597 (1.1)

Numbers are number (proportion), mean (SD) or median (IQR). Additional details

can be found in Supplementary table 1.

Genome-wide significant associations for postoperative delirium

Six independent, statistically significant SNPs were identified within a single genetic

risk region on chromosome 19 (Figure 2 and 3, Table 2). The lead SNP was

rs429358, a missense variant in the *APOE* gene that, together with rs7412, defines

the ε2/ε3/ε4 isoforms linked to Alzheimer's disease risk. A total of 26 genes were

mapped to this region, including four (*APOE*, *TOMM40*, *APOC1* and *PVRL2*) that

were significantly associated in MAGMA gene-level analysis (Supplementary table 2,

Supplementary Figures 1 and 2). Adding age as an additional covariate in the GWAS

identified one further independent significant SNP, rs12691088, an intronic variant of

the *APOC1* gene (Supplementary table 3).

Table 2 Independent significant single-nucleotide polymorphisms passing genome-

wide significance in case-control GWAS of postoperative delirium.

rsID*	Chr:position	Nearest gene	Function	Effect allele	OR (95% CI)	p

rsID*	Chr:position	Nearest gene	Function	Effect allele	OR (95% CI)	p
rs429358	19:45411941	*APOE*	exonic	T	0.56 (0.51-0.62)	1.40×10^{-26}
rs157592	19:45424514	*APOC1*	intergenic	A	0.6 (0.55-0.66)	2.03×10^{-21}
rs157582	19:45396219	*TOMM40*	intronic	C	0.66 (0.6-0.73)	1.13×10^{-15}
rs11556505	19:45396144	*TOMM40*	exonic	C	0.64 (0.58-0.71)	1.71×10^{-14}
rs10119	19:45406673	*TOMM40*	UTR3	G	0.72 (0.66-0.79)	6.46×10^{-12}
rs75627662	19:45413576	*APOE*	downstream	C	0.74 (0.67-0.82)	2.11×10^{-8}

*rsID: Reference SNP cluster ID

GWAS results after excluding existing or incident dementia

After excluding individuals with a pre-existing diagnosis of dementia (56 cases

(5.7%) and 375 controls (0.3%)), 5 of the 6 independent significant SNPs remained

significant. However, rs75627662 (a downstream variant of *APOE*) no longer

reached genome-wide significance. Three genes, *APOE*, *APOC1* and *TOMM40*,

remained significant on MAGMA testing (Supplementary figure 3 and 4). When

patients who went on to be diagnosed with dementia during UK Biobank follow-up

were also excluded (141 cases, 13.9%, and 2358 controls, 1.7%), two SNPs

remained genome-wide significant, rs429358 and rs157592. The MAGMA results

were unchanged (Supplementary figure 5 and 6).

GWAS results in cardiothoracic and non-cardiothoracic surgery groups

The results for the non-cardiothoracic surgery subgroup (798 cases, 126,973

controls) were similar to those in the overall cohort with five independent significant

SNPs identified in the same risk locus on chromosome 19 and three of the four

genes remained significant on MAGMA testing (*APOE*, *APOC1* and *TOMM40*). The

lead SNP was the same as in the primary GWAS and the other variants either

overlapped with the primary analysis or were in strong linkage disequilibrium ($r^2 >$

0.97) with them (Supplementary table 4). The cardiothoracic analysis was likely

underpowered and returned no genome-wide significant results at $p < 5 \times 10^{-8}$.

Multiple SNPs reached a lower indicative threshold of significance including the lead

SNP from the primary analysis, rs429358 ($p = 3.8 \times 10^{-7}$; Supplementary table 5).

Genetic correlation with Alzheimer's disease

Significant local genetic correlation was identified on chromosome 19 between

postoperative delirium and both delirium of all causes and Alzheimer's disease

(Table 3). The correlated region (chr19:45040933-45893307) encompassed the

independent significant SNPs from the primary GWAS.

Table 1 Results of Local Analysis of [co]Variant Association (LAVA) testing between

postoperative delirium GWAS results and FinnGen GWAS summary statistics.

FinnGen phenotype	Rho	R^2	p
Delirium (all)	0.63 (0.46-0.81)	0.40 (0.22-0.66)	3.7×10^{-10}
Alzheimer's disease	0.68 (0.57-0.80)	0.47 (0.32-0.65)	5.2×10^{-21}

Rho represents the local genetic correlation coefficient. R^2 represents the proportion

of variance in postoperative delirium explained by the comparator phenotype.

Association of genetic predisposition for Alzheimer's disease with postoperative

delirium

Prior to averaging, forty-two PGS for Alzheimer's disease were identified and passed

variant matching (Supplementary table 6). Increased polygenic risk for Alzheimer's

disease was associated with increased risk of postoperative delirium in the UK

Biobank cohort after adjusting for age and sex (adjusted OR [95% CI] PGS quintile

4: 1.49 [1.2-1.85], PGS quintile 5: 2.29 [1.87-2.8], p <0.001; Table 4).

Table 2 Odds ratio for postoperative delirium by Alzheimer's disease polygenic risk

score (PGS) quintile. Results are shown for all 42 polygenic risk scores, adjusted for

age and sex, and the subset which did not include the *APOE* region (15 *APOE*-

independent scores), adjusted for age, sex and *APOE* ε4 genotype.

Term	All scores (n=42)		*APOE*-independent scores (n=15)	
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
PGS quintile 1	1.00 (reference)	-	1.00 (reference)	-
PGS quintile 2	1.07 (0.85-1.35)	0.54	1.24 (1.00 – 1.53)	0.052
PGS quintile 3	1.25 (1-1.57)	0.047	1.32 (1.07 – 1.62)	0.01
PGS quintile 4	1.49 (1.2-1.85)	<0.001	1.24 (1.00 – 1.53)	0.049
PGS quintile 5	2.29 (1.87-2.8)	<0.001	1.50 (1.22 – 1.84)	<0.001
Age	1.22 (1.2-1.23)	<0.001	1.22 (1.20 – 1.23)	<0.001
Sex - male	1.82 (1.6-2.07)	<0.001	1.82 (1.60 – 2.07)	<0.001
APOE ε4 x1	-	-	1.75 (1.53 – 2.00)	<0.001
APOE ε4 x2	-	-	4.19 (3.25 – 5.41)	<0.001

Effect of Apolipoprotein E (APOE) genotype on the association of Alzheimer's

disease risk with postoperative delirium

Fifteen of the polygenic risk scores identified for Alzheimer's disease contained no

variants in the *APOE* region (*APOE*-independent scores, Supplementary table 6).

The effect size of increasing PGS quintile was reduced compared to *APOE*-inclusive

scores and the presence of one or more *APOE* ε4 isoforms was associated with

increased risk of postoperative delirium (Table 4).

Discussion

In this study, using a large national biobank with linked healthcare data, we identified

a genetic risk locus for postoperative delirium on chromosome 19 which included six

independent significant SNPs and four mapped genes meeting genome-wide

significance. Follow-up analyses in an independent cohort confirmed the presence of

shared genetic risk between postoperative delirium and Alzheimer's disease.

Previous GWAS which have included postoperative delirium as an outcome have

failed to find any genome-wide significant results, but were likely underpowered (13–

15). Our study, to the best of our knowledge the largest GWAS of postoperative

delirium to date, is substantially better powered than previous analyses and

implicates APOE – an established genetic determinant of Alzheimer's disease – in

postoperative delirium risk. The lead SNP identified (*rs429358*) remained significant

when patients with a pre-existing or subsequent diagnosis of dementia were

excluded, as did the significance of the *APOE* gene on MAGMA testing. We have

identified additional genes associated with postoperative delirium (*APOC1*, *TOMM40*

and *PVRL2*), which were previously reported to be associated with a range of

neurocognitive phenotypes including dementia, cognitive function and decline, brain

biomarkers and cerebral imaging metrics (Supplementary table 2, Supplementary

figure 7). We did not replicate the results of an earlier candidate gene study that

identified an association between the cholinergic genes *CHRM2* and *CHRM4* and

postoperative delirium (14) (all three identified variants showed null effects, see

Supplementary table 7). However, we used a genome-wide approach which has

methodological advantages including increased genetic coverage, reduced bias and

lower false positive rates and therefore represents a more robust analysis (29).

293 Post-GWAS follow-up analyses showed that genetic predisposition for Alzheimer's

294 disease is associated with risk of perioperative delirium, including a dose-response

295 effect of *APOE* ε4 allele count. Previous studies investigating the association

296 between *APOE* ε4 and postoperative delirium have shown mixed results. A recent

297 study of 19,331 patients (2086 of whom had postoperative delirium) found *APOE* ε4

298 carriers to be at increased risk of neurocognitive disorders compared with non-

299 carriers (30). However, the neurocognitive traits in this study were defined using

300 Phecodes – which include a wider range of medical diagnoses than the more

301 specific ones used in our study (31) – and the authors did not report the timepoint at

302 which outcomes were assessed. Several other studies have found no association

303 (32–34) whilst one small study (29 cases of postoperative delirium) did report

304 increased risk with the ε4 allele (35).

306 Taken together, these data suggest shared genetic architecture and risk for delirium,

307 whether postoperative or otherwise, and Alzheimer's disease, with multiple clinical

308 implications. Firstly, variants associated with postoperative delirium could be used to

309 risk-stratify patients ahead of surgery to permit alterations to the care pathway such

310 as perioperative care bundles (36). The use of existing polygenic risk scores for

311 related conditions (e.g. Alzheimer's disease) could add additional predictive benefit.

312 Secondly, the acute occurrence of postoperative delirium might be a marker of

313 underlying neurocognitive vulnerability or an undiagnosed chronic condition. If the

314 prediction of increased postoperative delirium risk is also a risk indicator for future

315 Alzheimer's disease then these patients may benefit from additional monitoring long-

316 term. Finally, our findings of shared biological pathways with Alzheimer's disease

could aid in the development of preventive measures for postoperative delirium. For

example, acetylcholinesterase inhibitors are widely used in the treatment of

Alzheimer's disease but definitive evidence of benefit for the prevention of

postoperative delirium is lacking (37,38). Identifying the patient group who might

benefit from acetylcholinesterase inhibitors could be one important outcome of

genetic studies.

The strengths of this study include the use of a large prospective cohort with linked

healthcare data that is subject to rigorous quality control and validation procedures.

We defined our exposure using published criteria and employed robust statistical

methods to deal with the large case-control imbalance. We were also able to extend

our findings through a range of post-GWAS analyses using an independent

validation cohort. The study does have some limitations. Whilst UK Biobank

represents a large cohort of patients there is a recognised "healthy volunteer"

selection bias (39) and so the results may not be entirely generalisable to the wider

UK population. Any secondary data analysis relying on routinely-collected

administrative data is limited by the fields available, with some potentially relevant

factors such as ASA physical status grade and type of anaesthesia not recorded.

Similarly, the diagnosis of delirium relied upon ICD-10 clinical coding and was not

prospectively screened for. Hospital coding for delirium is consistently found to have

low sensitivity but excellent specificity (40). As such we will likely have missed some

cases but any resulting bias would have reduced the observed effect, thereby

strengthening the validity of our findings. Whilst is also possible that some cases of

delirium preceded surgery, the risk of this was minimised as far as possible. Finally,

whilst rates of some comorbidities and surgical characteristics differed between

cases and controls, these variables may lie on the causal pathway or act as

selection-related colliders in a major surgical cohort. We therefore did not adjust for

them in the primary GWAS but examined their influence through a range of

sensitivity analyses which support the robustness of our findings.

In conclusion, we have used a large national biobank with linked healthcare data to

identify six SNPs and four genes associated with increased risk of postoperative

delirium. Data from an independent cohort suggests there is shared genetic

architecture and risk between postoperative delirium, delirium more broadly, and

Alzheimer's disease. These findings have potential clinical benefit through risk

stratification based on genotype or polygenic risk score data, early identification of

future Alzheimer's disease risk in the perioperative setting, and the identification of

biological targets for the prevention of postoperative delirium.

Authors' contributions

RAA: study design, data analysis, preparing first and subsequent drafts of the paper;

PY: study design, drafting paper; BG: study design, drafting paper; GK: study design,

drafting paper; TG: study design, drafting paper.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 128619. This includes linked data provided by patients and collected by the NHS as part of their care and support and data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058).

Quality Control filtering of the UK Biobank data used the process described by R.Mitchell, G.Hemani, T.Dudding, L.Corbin, S.Harrison, L.Paternoster(23).

This work was carried out using the computational and data storage facilities of the Advanced Computing Research Centre, University of Bristol (http://www.bristol.ac.uk/acrc/).

Declaration of interests

TRG receives funding from GlaxoSmithKline, Biogen and Roche for unrelated research. The other authors declare that they have no conflict of interest.

Funding

RAA is funded by a Wellcome Trust GW4-CAT PhD Programme for Health Professionals PhD Fellowship [316275/Z/24/Z]. RAA, PY, GMK and TRG are supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol (RA, TG: MC_UU_00032/3; PY: MC_UU_00032/4; GMK: MC_UU_0032/6). GMK acknowledges additional funding from the Wellcome Trust (grant numbers: 201486/Z/16/Z and 201486/B/16/Z), the Medical Research Council (grant numbers: MR/W014416/1; MR/S037675/1; MR/Z50354X/1; and MR/Z503745/1. PY, TRG, and GMK are also supported by the UK National Institute for Health and Care Research (NIHR) Bristol Biomedical Research Centre (grant number: NIHR 203315). The views expressed are those of the authors and not necessarily those of the UK NIHR or the Department of Health and Social Care.

References

1. Evered L, Atkins K, Silbert B, Scott DA. Acute peri-operative neurocognitive disorders: a narrative review. Anaesthesia. 2022;77(S1):34–42.

2. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. The Lancet. 2014 Mar 8;383(9920):911–22.

3. Gou RY, Hshieh TT, Marcantonio ER, Cooper Z, Jones RN, Travison TG, et al. One-Year Medicare Costs Associated With Delirium in Older Patients Undergoing Major Elective Surgery. JAMA Surg. 2021 May;156(5):462–70.

4. MacLullich AMJ, Ferguson KJ, Miller T, de Rooij SEJA, Cunningham C. Unravelling the pathophysiology of delirium: A focus on the role of aberrant stress responses. J Psychosom Res. 2008 Sep 1;65(3):229–38.

5. Cerejeira J, Firmino H, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. Acta Neuropathol (Berl). 2010 Jun 1;119(6):737–54.

6. Rump K, Adamzik M. Epigenetic Mechanisms of Postoperative Cognitive Impairment Induced by Anesthesia and Neuroinflammation. Cells. 2022 Sep 21;11(19):2954.

7. Swarbrick CJ, Partridge JSL. Evidence-based strategies to reduce the incidence of postoperative delirium: a narrative review. Anaesthesia. 2022;77(S1):92–101.

8. Schenning KJ, Deiner SG. Postoperative Delirium in the Geriatric Patient. Anesthesiol Clin. 2015 Sep 1;33(3):505–16.

9. Nadelson MR, Sanders RD, Avidan MS. Perioperative cognitive trajectory in adults. Br J Anaesth. 2014 Mar 1;112(3):440–51.

10. Goldberg TE, Chen C, Wang Y, Jung E, Swanson A, Ing C, et al. Association of Delirium With Long-term Cognitive Decline: A Meta-analysis. JAMA Neurol. 2020 Nov 1;77(11):1373–81.

11. Peden CJ, Miller TR, Deiner SG, Eckenhoff RG, Fleisher LA, Fleisher L, et al. Improving perioperative brain health: an expert consensus review of key actions for the perioperative care team. Br J Anaesth. 2021 Feb 1;126(2):423–32.

12. Abdellaoui A, Yengo L, Verweij KJH, Visscher PM. 15 years of GWAS discovery: Realizing the promise. Am J Hum Genet. 2023 Feb 2;110(2):179–94.

13. Rickenbacher M, Reinbold CS, Herms S, Hoffmann P, Cichon S, Wueest AS, et al. Genome-wide Association Study of Postoperative Cognitive Dysfunction in Older Surgical Patients. J Neurosurg Anesthesiol. 2022 Apr;34(2):248.

14. Heinrich M, Sieg M, Kruppa J, Nürnberg P, Schreier PH, Heilmann-Heimbach S, et al. Association between genetic variants of the cholinergic system and

postoperative delirium and cognitive dysfunction in elderly patients. BMC Med Genomics. 2021 Oct 21;14(1):248.

15. Westphal S, Stoppe C, Gruenewald M, Bein B, Renner J, Cremer J, et al. Genome-wide association study of myocardial infarction, atrial fibrillation, acute stroke, acute kidney injury and delirium after cardiac surgery - a sub-analysis of the RIPHeart-Study. BMC Cardiovasc Disord. 2019 Jan 24;19(1):26.

16. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018 Oct;562(7726):203–9.

17. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023 Jan;613(7944):508–18.

18. Genetic data | FinnGen [Internet]. [cited 2025 Sep 1]. Available from: https://www.finngen.fi/en/genetic_data

19.: External Info□: Data_providers_and_dates [Internet]. [cited 2024 Oct 9]. Available from: https://biobank.ndph.ox.ac.uk/showcase/exinfo.cgi?src=Data_providers_and_dates

20. Abbott TEF, Fowler AJ, Dobbs TD, Harrison EM, Gillies MA, Pearse RM. Frequency of surgical treatment and related hospital procedures in the UK: a national ecological study using hospital episode statistics. BJA Br J Anaesth. 2017 Aug 1;119(2):249–57.

21. Bupa - Code Search main [Internet]. [cited 2021 May 12]. Available from: https://codes.bupa.co.uk/procedures

22. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat Genet. 2021 Jul;53(7):1097–103.

23. Ruth Mitchell GH. data.bris. 2019 [cited 2024 Oct 9]. UK Biobank Genetic Data: MRC-IEU Quality Control, version 2. Available from: https://data.bris.ac.uk/data/dataset/1ovaau5sxunp2cv8rcy88688v

24. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017 Nov 28;8(1):1826.

25. Leeuw CA de, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. PLOS Comput Biol. 2015 Apr 17;11(4):e1004219.

26. Werme J, van der Sluis S, Posthuma D, de Leeuw CA. An integrated framework for local genetic correlation analysis. Nat Genet. 2022 Mar;54(3):274–82.

27. Lambert SA, Wingfield B, Gibson JT, Gil L, Ramachandran S, Yvon F, et al. Enhancing the Polygenic Score Catalog with tools for score calculation and ancestry normalization. Nat Genet. 2024 Sep 26;1–6.

28. Ware EB, Faul JD, Mitchell CM, Bakulski KM. Considering the APOE locus in Alzheimer's disease polygenic scores in the Health and Retirement Study: a longitudinal panel study. BMC Med Genomics. 2020 Nov 3;13:164.

29. Menon DK, Rosand J. Finding a Place for Candidate Gene Studies in a Genome-Wide Association Study World. JAMA Netw Open. 2021 Jul 26;4(7):e2118594.

30. Thedim M, Hu J, Maher M, Wiener-Kronish J, Saxena R, Vacas S. Perioperative polygenic and APOE-based genetic risk assessment for neurocognitive disorders: a biobank study. Br J Anaesth [Internet]. 2025 Jun 24 [cited 2025 Jul 4];0(0). Available from: https://www.bjanaesthesia.org/article/S0007-0912(25)00308-3/fulltext

31. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013 Dec;31(12):1102–11.

32. Abelha FJ, Fernandes V, Botelho M, Santos P, Santos A, Machado JC, et al. Apolipoprotein E e4 allele does not increase the risk of early postoperative delirium after major surgery. J Anesth. 2012 Jun 1;26(3):412–21.

33. Vasunilashorn S, Ngo L, Kosar CM, Fong TG, Jones RN, Inouye SK, et al. Does Apolipoprotein E Genotype Increase Risk of Postoperative Delirium? Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2015 May 21;23(10):1029.

34. Tagarakis GI, Tsolaki-Tagaraki F, Tsolaki M, Diegeler A, Tsilimingas NB, Papassotiropoulos A. The Role of Apolipoprotein E in Cognitive Decline and Delirium after Bypass Heart Operations. Am J Alzheimers Dis Dementias®. 2007 Jun 1;22(3):223–8.

35. Leung JM, Sands LP, Wang Y, Poon A, Kwok P yan, Kane JP, et al. Apolipoprotein E e4 Allele Increases the Risk of Early Postoperative Delirium in Older Patients Undergoing Noncardiac Surgery. Anesthesiology. 2007 Sep 1;107(3):406–11.

36. Meco BC, Jakobsen K, De Robertis E, Buhre W, Alkış N, Kirkegaard PR, et al. A first assessment of the safe brain initiative care bundle for addressing postoperative delirium in the postanesthesia care unit. J Clin Anesth. 2024 Oct 1;97:111506.

37. Gamberini M, Bolliger D, Lurati Buse GA, Burkhart CS, Grapow M, Gagneux A, et al. Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery—A randomized controlled trial*. Crit Care Med. 2009 May;37(5):1762.

38. Youn YC, Shin HW, Choi BS, Kim S, Lee JY, Ha YC. Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment. Int J Geriatr Psychiatry. 2017;32(10):1079–84.

39. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am J Epidemiol. 2017 Nov 1;186(9):1026–34.

40. Chuen VL, Chan ACH, Ma J, Alibhai SMH, Chau V. Assessing the Accuracy of International Classification of Diseases (ICD) Coding for Delirium. J Appl Gerontol. 2022 May;41(5):1485–90.

Figure legends

Figure 1 Study flow diagram.

Figure 2 Manhattan plot of GWAS results. The red line represents a genome-wide significant p value of 5×10^{-8}.

Figure 3 Q-Q plot of GWAS results. Genomic inflation factor (λ) 1.017.